Pharmaceutical Giants Shifted Toward Biotech Acquisitions

Biotech firms increasingly bypassed IPOs in 2026 as pharmaceutical companies pursued strategic mergers.

Updated on Sept. 25, 2026 in Biotech

Isometric editorial illustration showing a large research facility alongside a small metallic canister, representing corporate biotech acquisition trends.
Pharmaceutical companies, including Eli Lilly, are increasingly bypassing public market routes by acquiring biotechnology startups earlier in their development stages. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?

Pharmaceutical companies have increasingly turned to acquiring biotechnology firms rather than allowing them to pursue initial public offerings. This trend defined the 2026 landscape for cell and gene therapy development.

Why it matters

Biotech companies often require the mature commercial infrastructure of larger pharmaceutical entities, while pharmaceutical firms seek the specialized innovation and risk-taking capacity inherent in smaller biotechnology ventures.

In 2025, biotech IPOs raised $3 billion, a decline from $4 billion in 2023. Meanwhile, 2026 saw significant deals, including Eli Lilly committing a $3.25 billion upfront payment for Kelonia Therapeutics.

The players

Eli Lilly

Eli Lilly is a global pharmaceutical corporation that reported $65 billion in 2025 revenue and projects $90 billion for 2026.

AstraZeneca

AstraZeneca is a multinational pharmaceutical firm that agreed to pay $425 million for EsoBiotec in 2026.

AbbVie

AbbVie is a research-based biopharmaceutical company that completed its $2.1 billion purchase of Capstan Therapeutics in August 2026.

Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical firm that agreed to pay $1.5 billion for Orbital Therapeutics in October 2026.

The details

Pharmaceutical companies are now acquiring biotech firms at development stages that historically marked the traditional IPO window. Firms like Eli Lilly are utilizing massive revenue streams to consolidate specialized platforms directly into their pipelines.

Timeline

  1. Astellas acquired Ocata Therapeutics in 2016.

  2. Gilead Sciences bought Kite Pharma for $11.9 billion in 2017.

  3. Biotech IPOs raised $4 billion in 2023.

  4. Biotech IPOs raised $3 billion in 2025.

  5. Pharmaceutical M&A activity accelerated throughout 2026.

The Tech Race

This wave of consolidation follows the precedent set by the 2017 Gilead Sciences acquisition of Kite Pharma. Current industry strategies now prioritize direct integration over independent public listings to secure next-generation cell and gene therapy platforms.

Investors and consumers may see changes in treatment availability as specialized innovations move from independent labs to large-scale pharmaceutical pipelines. These mergers can streamline access to advanced therapies but may also reduce the number of independent firms available for public investment.

The takeaway

The shift toward acquisition suggests that major pharmaceutical players are increasingly confident in their ability to scale biotech innovation internally. Stakeholders should track these consolidation patterns as they indicate which specific therapeutic platforms are deemed most commercially viable.

Further reading

For more on industry trends, visit Biotech.

Source note: This article includes information reported by BioXconomy.

Live Poll

Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?